BlossomHill Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from BlossomHill Therapeutics, Inc.'s yearly results, compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than almost all Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
—Data incomplete
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-9,385.0×Operating cash was negative last year, while some debt falls due within a year.
Lower than almost all Healthcare companies in United States.
Cash Cushion Ratio
+23%Cash, after subtracting all debt, equals 23% of its market value (net cash).
Higher than 65% of Healthcare companies in United States.
Tangible Assets Ratio
100%Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 96% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (8)
BlossomHill Therapeutics, Inc. made a loss over the last year. BlossomHill Therapeutics, Inc. owes $2.41 for every $1 it owns. BlossomHill Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossBlossomHill Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-2.88BlossomHill Therapeutics, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$503 MThe total market value of all of BlossomHill Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 55% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
NegativeBlossomHill Therapeutics, Inc.'s net worth is negative ($175 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
2.41×BlossomHill Therapeutics, Inc. owes $2.41 for every $1 it owns, so it owes more than it owns, higher than 97% of Healthcare companies in United States.
Dividend yield
NoneBlossomHill Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossBlossomHill Therapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashBlossomHill Therapeutics, Inc. held $114 M more cash than debt (net cash) at Dec 2025.
Questions
How much does BlossomHill Therapeutics, Inc. owe compared with what it owns?
BlossomHill Therapeutics, Inc. owes $2.41 for every $1 it owns, so it owes more than it owns, higher than 97% of Healthcare companies in United States.
Does BlossomHill Therapeutics, Inc. pay a dividend?
No. BlossomHill Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.